<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02694588</url>
  </required_header>
  <id_info>
    <org_study_id>Short-Sys-Inflame</org_study_id>
    <nct_id>NCT02694588</nct_id>
  </id_info>
  <brief_title>Clinical and Molecular Phenotyping in IBD</brief_title>
  <acronym>Phen_IBD</acronym>
  <official_title>Systematic Profiling of Anti-inflammatory Drugs for the Detection of Drug- Specific Response Signatures in the Treatment of Chronic Inflammatory Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory bowel disease (IBD) and psoriasis (Ps) are common, chronic, immune- mediated
      barrier diseases with shared inflammatory pathways. Current therapeutic interventions with
      anti-cytokine antibodies (TNF-Î±, IL-23/IL-12) reflect the intent to disrupt specific pathways
      of inflammatory immunopathology. Individual responses to biological treatment can be thereby
      be exploited in a systems biology approach that employs a targeted mechanism of action (MOA)
      to decipher molecular signatures of therapeutic responses in the context of a distinct
      disease entity. Using a translational approach to investigate clinical and molecular
      phenotypes during therapeutic interference with cytokine signaling and leukocyte trafficking,
      the investigators aim to trace common and unique signatures of drug- and therapy-specific
      responses.

      Patients will undergo endoscopic evaluation of the mucosal surface and gastrointestinal wall
      by conventional HD-colonoscopy, endoscopic ultrasound and confocal laser endomicroscopy prior
      to and during specific therapies with biologicals. In parallel, mucosa samples will be
      obtained to define molecular phenotypes during the course of therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mucosal healing week 2</measure>
    <time_frame>week 2</time_frame>
    <description>Scoring of mucosal healing according to endoscopic Mayo score at week 2 after initiation of therapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>IBD</condition>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg/kg body weight, week 0/2/6, then every 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vedolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mg, week 0/2/6, then every 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody</description>
    <arm_group_label>Infliximab</arm_group_label>
    <other_name>Endoscopic assessment after Infliximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vedolizumab</intervention_name>
    <description>HD-endoscopy, CLE, endoscopic ultrasound after application of Anti-Integrin antibody</description>
    <arm_group_label>Vedolizumab</arm_group_label>
    <other_name>Endoscopic assessment after Vedolizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  inflammatory bowel disease

          -  indication for biological therapy

        Exclusion Criteria:

          -  pregnancy, breast feeding

          -  no written informed consent to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Schreiber, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>00494315971272</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Ellrichmann, MD</last_name>
    <phone>00494315972075</phone>
    <email>mark.ellrichmann@uksh.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Department I, University Hospital Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Ellrichmann, MD</last_name>
      <phone>00494315972075</phone>
      <email>mark.ellrichmann@uksh.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2016</study_first_posted>
  <last_update_submitted>June 17, 2016</last_update_submitted>
  <last_update_submitted_qc>June 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Mark Ellrichmann</investigator_full_name>
    <investigator_title>Head of Interdisciplinary Endoscopy</investigator_title>
  </responsible_party>
  <keyword>Vedolizumab</keyword>
  <keyword>Infliximab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Vedolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

